Drugs / Nelitolimod
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07172282 | Nov 2025 → Nov 2027 expected | colorectal cancer | Northwell Health | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nelitolimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172282 ↗ |
| Known as | SD-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068457 ↗ |
| Known as | SD-101 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068457 ↗ |
| Action | Activate | “TLR9 agonist” NCT07172282 ↗ |
| Route | Other | “administered regionally to the liver via a TriNav Pressure Enabled Drug Delivery (PEDD) catheter” NCT07172282 ↗ |
| Target | TLR9 | “binds to TLR9 receptors” NCT07172282 ↗ |